Cannabinoids

768 Subject Index

prolactin 562
proliferation responses 395
proopiomelanocortin 561
propofol (2,6-diisopropyl phenol)
193
proprioception 438
protostomes 285
protostomian 291, 292, 294
psychostimulants 131
Purkinje cell(s) 288, 341, 342, 355
putamen 354

QSAR
CoMFA 262, 263
QSAR techniques
CoMFA 256
modifiedactiveanalogapproach
256
multiple linear regression anal-
yses 256

R-(+)-methanandamide
seemethanandamide
R-(+)-WIN55212(WIN55,212-2) 8,
14,16,28–33,35–37,55,236,
250, 428, 605, 608, 617
radial maze 453
Raf 62
RANTES 397
raphe 433
raphe nucleus 315
RAW264.7macrophagecellline 393
RAW264.7macrophage-likecells 392
rCBF 427
receptor occupancy 427
reflux 574, 580, 592
release of excitatory and inhibitory
neurotransmitters 4
renal arteries 346
reperfusion damage 617
reproductive function 562
reptiles 290
reticular formation 315
retina 342
retrograde 284, 288
retrograde neurotransmitter 135

retrograde signalling 356

metabotropic glutamate recep-

tors 371

postsynaptic 371, 372

presynaptic 371, 372

rewarding effects 692

conditioned place preference

692, 693

drug self-administration 692

drug-self administration

studies 693

electricalself-stimulation 693

intracranial self-stimulation

693

rewarding properties 693

rimonabant (SR141716) 736, 748

rostral ventromedial medulla oblon-

gata 337, 339

Saccoglossus kowalevskii 291

safety issues with cannabis-based

medicines 739

SAR

cannabinoid receptor agonists

212–222,226–231,233–236,

250, 251

cannabinoid receptor anta-

gonists 223–225,231,232,

251–252

Sativex 727, 731, 742

schizophrenia 432

sciatic nerve 318

sea urchin 287, 291

secondary humoral immune

response 390

selectivity 211

sensory nerve terminals 613, 614

septum 310

sequence

human CB 1 receptor 249

human CB 2 receptor 249

serotonin 342, 343

serotonin-3 (5-HT 3 ) receptor 35,

36, 310, 330, 734

Sertoli cells 564

shock 600, 615, 616, 618